Onderneming Revelation Biosciences, Inc.
Aandelen
REVB
US76135L5075
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,445 USD | +3,16% | +13,21% | -84,02% |
Vakgebied
Aantal werknemers: 9
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Rolke
CEO | Chief Executive Officer | 55 | 01-05-20 |
Chester Zygmont
DFI | Director of Finance/CFO | 44 | 01-05-20 |
Sandra Vedrick
IRC | Investor Relations Contact | - | - |
Robin Marsden
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Tidmarsh
CHM | Chairman | 64 | 01-05-20 |
Jess Roper
BRD | Director/Board Member | 59 | 01-10-20 |
James Rolke
CEO | Chief Executive Officer | 55 | 01-05-20 |
Lakhmir Chawla
BRD | Director/Board Member | 53 | 27-09-23 |
Jennifer Carver
BRD | Director/Board Member | 70 | 01-05-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 632 935 | 1 627 645 ( 99,68 %) | 0 | 99,68 % |
Bedrijfsgegevens
Revelation Biosciences, Inc.
4660 LaJolla Village Drive Suite 100
92122, San Diego
+650 800 3717
http://www.revbiosciences.comSector
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-84,02% | 3,87 mln. | |
+21,76% | 47,9 mld. | |
+46,62% | 41,42 mld. | |
-2,18% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+10,19% | 25,55 mld. | |
-20,87% | 19,27 mld. | |
-0,32% | 12,15 mld. | |
+31,04% | 12,14 mld. | |
-0,47% | 11,99 mld. |
- Beurs
- Aandelen
- Koers REVB
- Onderneming Revelation Biosciences, Inc.